Forecast & Rating8 analysts currently cover Crescent Biopharma, with about 87.5% giving a positive rating — meaning they expect the stock to rise. The average price target is $30.60, about 72.4% upside from the current price of $17.75. Price targets span a fair range, indicating some disagreement among institutions. For you, this means most professionals who study Crescent Biopharma closely still see room for the stock to rise. Data as of Aug 26, 2026; for reference only and not investment advice.
Aug 26, 2026Price forecast
$30.6072.39%
Forecast & RatingStrong buy
8analysts
- Strong buy75.00%
- Buy12.50%
- Hold12.50%
- Sell0.00%
- Strong sell0.00%
Target price forecast
Forecast dateAug 27, 2026
Forecast met39.3%
Stock price$17.75
Avg. target$30.6
High target$35
Low target$27
Analyst ratings
Strong buy
Buy
Hold
Sell
Strong sell
Source: S&P Global
This information is for reference only and is not investment advice.